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Abstract 
 
Cutaneous melanoma (CM) is an aggressive fatal skin malignancy arises in 
proliferating pigment producing melanocytes. Its characterized by ABCDE criteria, 
and diagnosed by applying this mnemonic rule, with other auxiliaries such as 
dermoscopy, distal dermoscopy and biopsy. This type of melanoma includes four 
different types, SSM, NM, LMM, and ALM. CM is caused mainly by direct UV 
exposure to the sun, tanning beds and other DNA mutations such as BRAF and 
NRAS.  
Mucosal melanoma (MM) is more aggressive than CM, which results from 
melanocytes proliferation of mucosal membranes mainly in respiratory, 
gastrointestinal and urogenital tracts. Unlike CM, which is widespread in males, 
MM is more frequently encountered in females with a female to male ratio of 1.85-
1.00.  
This type of melanoma is poorly diagnosed at early stages of the disease because 
of its location in unexposed body sites and the absence of early symptoms. One of 
the risk factors implicated in sinonasal MM is formaldehyde exposure while 
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smoking can be involved in oral MM. C-kit is considered the most common 
mutation associated with MM. 
Melanoma staging is determined based on tumor thickness, nodal involvement 
degree and tumor metastases, and it divided into five progressive stages. The 
treatment varies according to patient’s status, which could be surgical removal, 
radiotherapy, chemotherapy, and mono-therapy.  
Twenty-four melanoma cell lines, 13 CM, 8 MM, and 3 acral obtained from 
Palestinian patients with melanoma were used in this study. These cell lines were 
grown and maintained following established procedures in the tissue culture 
laboratory. DNA was extracted by the salting out method and used for subsequent 
amplification and sequencing. These procedures were used to detect mutations in 
the following oncogenes: BRAF exon 15, NRAS Q16 exon 3, and CKIT exons 11, 
13, and 17.  
The sequencing results detected mutations in BRAF 57.1%, NRAS 14.2%, KIT 
29%, where KIT 11, 14.2%, KIT 13 14.2% and no mutations were detected in KIT 
17.  
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 ملخص الرسالة
 
. الصبغيةالخلايا  نتيجة لنموالخبيثة الفتاكة.   ينشأ هذا المرض  الامراض السطحي منيعتبر سرطان الجلد 
وتشخيصها بالإضافة الى هذا المقياس باستخدام عوامل أخرى  EDCBAيمكن وصف هذه الخلايا بمقياس 
. يوجد أربعة أنواع مختلفة من yspoiB dna ypocsomred latsiD ,ypocsomreDمساعدة مثل 
التعرض للأشعة فوق البنفسجية  إثرنتجت جميعها  MLA dna ,MML ,MN ,MSSسرطان الجلد: 
بغض النظر عن مصدر  مسمرا.وجعله  ودهمدبغ جلل التي يتعرض لها الاشخاص للشمس، الاشعةالمباشرة 
     الحمض النووي  مثل  في بنشوء طفراتة فاالتعرض لها لفترات طويلة يتسبب الاشعة فوق البنفسجي
 .SARNو  FARB
 
 
 في الصبغيةالخلايا  انتشار ةجي، نترطان الجلد السطحيسرطان الجلد المخاطي هو أكثر عدوانية من س
، الذي هو MCالجهاز التنفسي، الجهاز الهضمي والمسالك البولية التناسلية. على عكس ك الأغشية المخاطية
-58.1في الإناث مع نسبة الإناث إلى الذكور من  تواجداهو أكثر  MMعلى نطاق واسع في الذكور، 
في  تواجدهمن المرض بسبب  المتأخرةفي المراحل  الايتم تشخيصه لا النوع من سرطان الجلد  ا. هذ00.1
سرطان الجلد عوامل الخطر المتورطة في  أحدوغياب الأعراض المبكرة.  المكشوفةمواقع الجسم غير 
يلعب دور في حدوث هذا  التدخين يمكن أن انف الفورمالديهايد، بالإضافةلمادة هو التعرض المخاطي 
  بهذا النوع من سرطان الجلد.الطفرة الأكثر شيوعا المرتبطة  TIKC. ويعتبر المرض
 
 
ى انتشاره في العقد الليمفاوية من جهة وأعضاء مدلورم، وعلى سمك ابالاعتماد يتم تحديد الورم الميلانيني 
يختلف العلاج  المرض.عند تشخيص هذا  متتاليةخمس مراحل يمكن التعرف على  الجسم من جهة أخرى. 
الإشعاعي، العلاج الكيميائي،  علاجال، اجراحي الورم وفقا لحالة المريض، والتي يمكن أن تكون إزالة
 والعلاج الأحادي.
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خلايا سرطان جلدي  31خلايا سرطان الجلد،  عينة منفي هذه الدراسة أربعة وعشرون استخدمت 
تم الحصول عليها من المرضى  جلدي من الأطراف.  سرطان 3و، سرطان جلدي مخاطي 8، سطحي
الإجراءات المعمول  باتباعالفلسطينيين الذين يعانون من سرطان الجلد. تم زراعة هذه الخلايا والحفاظ عليها 
وتستخدم  ابها في مختبر زراعة الأنسجة. تم استخراج الحمض النووي بواسطة طريقة التمليح خارج
التالية: جراءات للكشف عن الطفرات في الجينات المسرطنة لتضخيم لاحق والتسلسل. وقد استخدمت هذه الإ
 .71 و 31و 11 إكسون TIKCو، 3اكسون  SARN، 51اكسون FARB
 
 TIKC٪، حيث 92 TIKC٪، 2.41 SARN٪، 1.75 FARBكشفت نتائج التسلسل عن طفرات في 
 .71 TIKC٪ ولم يتم الكشف عن أي طفرات في 2.41 ،31 TIKC٪، 2.41، 11
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1. Introduction 
1.1. Cutaneous Melanoma  
1.1.1. Definition, Clinical Characteristics and Diagnosis
CM is long been considered a highly heterogeneous disease1.  It is one of the major 
aggressive types of skin tumors, abnormally arising by proliferation of 
melanocytes in the epidermis2, and it is potentially recognized as fatal among 
overall skin cancer types3. CM is responsible for about 75 % of all deaths from 
skin cancers even though it forms only around 3-5 %4. Tumor metastasis to distant 
organs is accountable for the majority of melanoma related death. Only 14% of 
metastatic melanoma patients survive for 5 years and the reason for that referred to 
the diagnosis at late stages, whereas the large majorities, which account for more 
than 85% of patients diagnosed with melanoma, cured due to diagnosis at early 
stages of tumor progression5.  
 
The early detection and clinical guide of melanoma diagnosis follows the ABCDE 
criteria. This criteria stands for asymmetry of the lesion, borders irregularity, color 
variation which is different from one region to another; dissimilar shades of tan, 
brown, black; sometimes red, white, or blue within the same lesion. Diameter, 
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which is usually, more than 6 mm6 and finally evolving lesion which helps in the 
evaluation especially if it arises from mole, which will be different in size, shape 
and color from the other normal ones in the body7.  Hence, ABCDE criteria is 
considered the reference clinical characteristics of melanoma skin lesions; 
however, the most experienced clinicians have problems and difficulties 
diagnosing pigmented lesions properly, and clinical accuracy of diagnosis 
infrequently outrun 60%. Even though, CM may not be simply diagnose by 
applying ABCDE mnemonic rule8. Therefore, pathological examination must be 
performing for the diagnosis9. 
 
Early melanoma diagnosis may do using dermoscopy, and digital dermoscopy. The 
method that has been considered a useful tool to increase the accuracy in 
melanoma diagnosis by 10-27%10and gives diagnosis in early stages even in the 
absence of specific criteria for malignancy11. To complete the diagnosis and obtain 
accurate results, biopsy must take since it is an essential and initial step in the 
management of malignant melanoma and any suspicious lesion must be biopsied12. 
Excision biopsy is the recommended technique for suspected melanoma tumor as it 
enables diagnosis, staging, treatment, and determines future examination, while 
incision biopsy is suitable only for large lesions in some sensitive regions like the 
face and in the regions of a recent change within a giant congenital naevus13. 
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Biopsies, such as punch and shave are not recommended, because they do not 
permit total histological staging14. 
 
1.1.2. CM Subtypes 
Four main histopathological types of melanoma has been recognized, the 
superficial spreading melanoma “SSM”, nodular melanoma “NM”, lentigo 
maligna melanoma “LMM”, and acral lentiginous melanoma “ALM”15.  
 
I. Superficial spreading melanoma “SSM” 
SSM considered the most common type of CM since it accounts for about 65% of 
all melanoma cases diagnosed16.  Initially, it starts as slow radial growth phase 
(RGP) before becoming invasive, with a clinical characteristic of asymptomatic 
brown or black patch that could be asymmetric with irregular borders, or variations 
in color17. 
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II. Nodular Melanoma “NM”  
NM is the second most common subtype of CM that accounts for 15-30% and 
around 40% to 50% of other melanomas thicker than 2 mm 18 . Unlike other 
melanoma subtypes, NM has a vertical growth phase (VGP) of melanocytes which 
grow gradually as a round nodule that ulcerate, crust and bleed in advanced 
stages19. Hence, it has been rapidly invasive, aggressive, ulcerated, with more 
mitotic activity compared to SSM type 20 . NM differs from other subtypes of 
melanomas since they originate from different stem cell types, this is, dermal stem 
cells whereas the other subtypes arise from epidermal stem cells21. NM is 80% 
symmetrical with regular border and single color, which mostly could be red, or 
pink that regularly spread throughout the lesion. Therefore, ABCDE mnemonic 
rule is unhelpful, and EFG rule is another suggested aide that has been introduced 
for the identification of clinical features of NM that stands for elevated, firm and 
progressively growing lesion for more than a month22. 
 
III. Lentigo Maligna Melanoma “LMM” 
This type of pigmented lesions develops with time from lentigo maligna “LM” to 
become invasive LMM after it increases in size23. Mainly it occurs because of sun 
exposure that leads to skin damage particularly in the head and neck regions24. It 
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accounts for 4-15% of CM and occurs less commonly than SSM and NM25. LMM 
lesions are usually flat and slightly raised in certain areas, irregular borders, hyper 
pigmented with multiple colored varies from brown to black26.  
 
IV. Acral Lentiginous Melanoma “ALM”  
ALM is a very aggressive tumor27. It occurs on volar surfaces of hands and feet, 
subungual sites, and fingers or toes28. This type of melanoma has a slow RGP and 
central plaque like thickening. Also deeply pigmented tumor cells, obviously 
thickened papillary dermis, and diffuse reticular infiltration, all are considered the 
most common characteristic of ALM, lesions are remarkably large and in most 
cases they are thick and ulcerated29, However, it is described to have a poorer 
prognosis than melanomas of other histotypes 30 . ALM accounts for 5% of all 
melanomas31. However, population database shows that, it is linked with a worse 
prognosis than any other CM 32 . The molecular hallmarks of ALM 
are CCND1amplifications or somatic mutations in c-KIT 33 . KIT mutations are 
common in ALM and it accounts 23%34.  
 
 
10 
 
Figure 1: Superficial spreading melanoma “SSM”. 
 
Figure 2: Nodular Melanoma “NM”. 
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Figure 3: LentigoMaligna Melanoma “LMM” 
 
Figure 4: Aral Lentiginous Melanoma “ALM”  
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1.1.3. Causes and Risk Factors  
There are several environmental or genetic factors are involved in causing 
melanoma. The most important environmental factor associated with CM is 
exposure to ultraviolet (UV) radiation from the sun. The disease progression is 
associated directly to the UV wavelength, which ranges from 100 - 400 nm35. 
Those are largely categorizing into UV A light “315-400” nm, which reaches the 
earth’s surface almost unabsorbed. UV B “280-315” nm which is incompletely 
absorbed by the atmospheric ozone layer, and UV C “100-280” nm which is 
entirely absorbed by the earth’s atmosphere36.The most common primary DNA 
mutations are induced by UV B irradiation occurring at DNA sites having 
pyrimidine, giving primary photo products cyclobutane pyrimidine dimers and 6-4 
pyrimidine-pyrimidone, which cause DNA mutations if not removed by cellular 
repair activity37.While the mutations occurring after exposure to UV A irradiation 
lead to purine photo- adduct formation, so Guanine bases are altered and converted 
to 8-hydroxydeoxyguanosine (8-OHdG) which acts as a miscoding lesion resulting 
in G to T transversions38.  
Other non-solar UV source that plays an important role in causing melanoma is 
tanning beds, and there is strong association between the UV dose response 
tanning bed used and the risk of melanoma. The association is stronger for 
patient’s exposure at a younger age39. 
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 At the molecular and genetic levels, SSM and NM have a much advanced 
frequency of BRAF and NRAS mutations than other melanoma subtypes, whereas 
ALM and MM of the genital region have much higher probability to the presence 
of  KIT mutations40. 
 
2.  Mucosal Melanoma 
2.2.1. Definition, Clinical Characteristics and Diagnosis 
Primary mucosal melanoma (MM) arises from melanocytes found in the mucosal 
membranes lining respiratory, gastrointestinal and urogenital tracts. MM is rare, 
but it is more aggressive and has less favorable prognosis compared to other 
subtypes of melanoma. Since, this condition is rare, knowledge and information 
about its pathogenesis and risk factors are insufficient. Furthermore, protocols for 
staging and treatment of this type of melanoma41 are not well recognized. 
 
MM may occur in any mucosal surface in the body, but the most familiar and 
regular areas where it occurs are the head, neck, the anorectal mucosa, and the 
vulvo vaginal mucosa. MM unlike CM, which is more widespread in males, is 
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more frequently diagnosed in females with a ratio 1.85-1.0. vulvo vaginal 
melanoma frequency in females has been considered  the most common subtype, 
whereas head and neck are the most common areas that affect men 42 . MM 
represents only about 1.4% of all melanomas43. There are various manifestations of 
MM with different symptoms, e.g., in the respiratory track the most common 
symptoms observed are unilateral nasal obstruction, mass lesion, and epistaxis44. 
While the symptoms found in the gastrointestinal track, include abdominal pain, 
weight loss, upper gastrointestinal bleeding and anemia 45 . The most common 
presenting symptoms in MM of urogenital tract are vaginal bleeding and discharge, 
presence of mass lesion, and less common pain46.  
 
In general, the diagnosis of MM is poorly recognized at early stages of the disease 
because of the hidden sites and the absence of early symptoms. Confirmation 
mainly obtained at late stage when several lesions become ulcerated. Therefore, 
this condition is not easy assessed. The nonappearance of junctional change in an 
ulcerated lesion does not prevent the possibility that the lesion is a primary 
melanoma47.Immunohistochemical staining positive for protein S-100, HMB-45, 
Melan-A, Mart-1 and tyrosinase support diagnosis of melanoma48. 
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2.2.2. Causes and Risk Factors 
MM is different from CM where it occurs in areas that are not exposed to the sun. 
Therefore, the risk factors for the progression of this type of melanoma have not 
been recognized. One of the risk factors suggested for sinonasal MM is 
formaldehyde exposure. Therefore, exposure to formaldehyde considered a 
professional hazard among staff exposed to this substance 49 . For oral MM, 
cigarette smoking was proposed as risk factor, because it has been confirmed that 
oral pigmented lesions are more widespread among smokers50.  
 
At the molecular and genetics level, there is a strong association between C-KIT 
gene mutation and MM. In addition, other gene mutations that affect the PTEN and 
P53 tumor suppresser genes may be involved. Other mutations that lead to this 
type of melanoma include mutation in GNAQQ209 gene in exon 5 
andGNA11R183 gene mutation. The details about these mutations exist in the 
mutations section.  
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2.2.3. Mucosal melanomas of the respiratory tract 
 
MM in the respiratory tract found mainly in the nasal cavity and paranasal sinuses, 
whereas it is very uncommon in the mucosa of larynx or tracheobronchial tree. On 
the other hand, lungs considered the most common site for metastatic MM, and 
other types of melanoma like ocular and CM51. Although MM of the respiratory 
tract is most common in nasal cavity, paranasal sinuses and nasopharynx, it 
considered a rare tumor and accounts for about 4% of all sinonasal malignancies52, 
whereas nasal cavity is central site accounting for about 80% of melanomas in 
sinonasal tract53. Elderly are more susceptible for sinonasal tract MM with a mean 
age of 64 years54.  
 
There are several symptoms have been noticed in MM of respiratory tract, 
including unilateral nasal obstruction, mass lesion, epistaxis, also pain and facial 
distortion may occur with proptosis and diplopia which are rare in advanced stages. 
Those patients occasionally diagnosed due to the occult location of melanoma. The 
ones who started with epistaxis typically refer to physician earlier than the ones 
17 
 
with obstructive symptoms. Therefore, macroscopically, most of tumors appear as 
ulcerated polypoid brown to black pigmented mass55. 
Despite the possible difficulties encountered with surgical removal, which is 
limited by surrounding structures, it remains the main treatment of choice because 
even radiotherapy has not shown improvement in overall patient’s survival56.  
 
2.2.4. Mucosal melanoma of the gastrointestinal tract  
The most common sites where MM occurs in gastrointestinal tract are anorectal, 
with a ratio of 31.4% in the anal canal, 22.2% in the rectum, oropharyngeal area 
with 32.8% ratio, esophagus 5.9%, stomach 2.7%, small bowel 2.3%, gallbladder 
1.4%, and large bowel 0.9%, which is very uncommon site of origin 57 . 
Approximately 50% of gastrointestinal MM patients are older than 70 years, and 
14% are younger than 50 years. The colon, stomach and small intestine considered 
the most common areas of metastatic MM in gastrointestinal tract58.  
 
Oral melanomas arise initially from melanocytes normally exist in oral mucosa59. It 
has been verified that the concentration of melanocytes in the lower lip increase 
with age especially in men, hence the mean age of this type of melanoma is 59 
18 
 
years. Oral melanoma typically arise de novo, but it progresses from pre-existing 
melanocytic lesion in almost one third of patients60. It may occur in any place of 
the oral cavity, but hard palate and maxillary gingiva considered the most common 
affected areas, while other areas such as mandibular gingiva, labial and buccal 
mucosa, tongue, tonsils, uvula and parotid gland are rarely affected61. In this type 
of melanoma, the patient initially will be asymptomatic, presenting macular and 
flat lesion and sometimes it could be slightly elevated and irregular pigmented 
lesion. In later stages of the tumor prognosis, the lesion swells and becomes 
ulcerated, bleeds and cause pain with occasional tooth mobility sometimes 62 . 
Patients with oral melanoma show 25% regional lymph node metastases. In this 
case, surgery is considered the main treatment option, and can be accompanied 
with radiotherapy and chemotherapy. Despite all measures taken, prognosis 
remains poor63.  
 
Mucosal melanoma of the esophagus is a very rare tumor that accounts for 10.2% 
of all esophageal malignances. It occurs typically in the middle and lower part of 
esophagus since the melanocytes are concentrated there. Their number increased in 
areas of hyperplastic epithelium and chronic esophagitis, while approximately 10% 
of cases are located in the upper third of esophagus64. On the other hand, the 
melanocytes in the stomach and intestinal epithelium have not been demonstrated. 
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Therefore, the origin of melanoma in these sites remains unknown. The same can 
be applied to the primary melanoma of the small intestine with possible 
explanation pointing melanoblasts the origin on the tumor, which migrate to the 
distal ileum through the omphalomesenteric canal. Another suggestion says; all 
melanomas in the small intestine arise by metastases from unidentified primary 
CM65.  
 
MM which occurs in the ano-rectal area, is considered the most common one 
amongst primary melanomas of the gastrointestinal tract, and the third most 
common site after cutaneous and ocular melanomas66. Lesions may affect anal 
canal, rectum or both, but the most common ones are located within 6cm of the 
anal rim. Wide local excision is the initial treatment of choice in this case67. In 
contrast, the primary melanoma of the biliary tract is very uncommon and may 
arise in the gall bladder or bile duct. 9 cases of bile duct melanoma were reported 
in the literature, and 30 cases of melanoma in the gallbladder68. Melanomas on the 
biliary tract are metastatic widely, and tend to be found as multiple, smooth 
pigmented lesions, while the primary tumors are found as singular, polypoid lesion 
on gross examination69.  
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2.2.5. Mucosal melanoma of the urogenital tract  
MM may occur in any part of the urogenital tract including the vagina, uterine 
cervix, vulva, urethra and urinary bladder. This type of melanoma is more common 
in females than males, accounting for18% of genital tract and 3% of urinary tract70. 
Amongst genital tract in females, the most common occurrence is in vulva which 
accounts for 76.7% and considered the most common tumor  after squamous cell 
carcinoma in the vulva, followed by vaginal MM which accounts for 19.8%, 
whereas cervical melanoma has the least occurrence71.  
 
Vulvar melanoma frequently occurs in old women, with an average age 68 years72. 
Clitoral zone, labia majora and minora and peri-urethral are the most common sites 
where urogenital MM may occur, whereas vaginal introitus is the least common73. 
There are major symptoms that are associated with this type of melanoma 
including bleeding, vulvar mass, pruritus and irritation, with discomfort and 
discharge74.  
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3.  Melanoma Staging and Treatment 
Melanoma staging is determined based on the TNM classification system, which 
take into account the tumor thickness, nodal involvement degree and tumor 
metastases75.  
There are five stages of melanoma: 
  Stage 0, known as in situ melanoma, it is confined to the epidermis only 
without spreading into deeper layers. 
 Stage I, is also confined to the skin and do not spread, but thicker up to 1 
mm. This stage divided into two parts:  
o  Stage IA, the skin that covers melanoma is still intact. 
o Stage IB the skin covering melanoma is broken and ulcerated76.  
 
 Stage II, the melanoma is thicker ranging from 1.01 – 4 mm. It is not spread 
to other parts of the body including lymph nodes. Ulceration may or may not 
be seen. Stage II is divided into three parts: 
o Stage IIA, the melanoma thickness ranges between 1-2 mm and ulcerated, or 
between 2-4 mm without ulceration.   
o Stage IIB is ulcerated with 2-4 mm thickness or un-ulcerated with thickness 
more than 4 mm. 
o Stage IIC is ulcerated with more than 4 mm thickness77.  
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 Stage III, melanoma has spread to one or more lymph nodes or near skin. 
It’s divided into three stages:  
o Stage IIIA, is not ulcerated and extend into up to three lymph nodes which 
are not enlarged in close proximity to the primary tumor.  
o Stage IIIB, where the same spreading to 1-3 lymph nodes without 
enlargement has seen. In this stage the lesion is ulcerated, but could also 
be un-ulcerated with enlargement of the lymph nodes or un-ulcerated and 
spread to tiny areas of skin or lymphatic channels, but nearby lymph 
nodes do not have melanocytes. 
o Stage IIIC, where melanocytes have seen in lymph nodes or lymph 
channels, and in small areas of skin surrounding those areas. It may be 
seen as ulcerated and spread to 1-3 enlarged lymph nodes. It may spread 
to more than 4 mm with or without ulceration. 
 
 Stage IV, the melanoma has spread to distinct lymph nodes far from the 
primary site of melanoma and reaches several internal organs elsewhere in 
the body. It may be seen in parts of the skin far from the primary site. Lungs, 
liver and brain have all considered the most common sites of metastatic78.  
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There are different options for melanoma treatment. The first is by the surgical 
removal of the primary lesion, ensuring total removal of the lesion and the 
surrounding areas that may contain melanoma cells. This radical treatment 
prevents possible recurrence. Definitive surgical treatment typically should occur 
no later, than three to four weeks after biopsy result79. Surgical excision takes into 
consideration a safety margin of additional 1 cm in tumors up to 2 mm thick, and 2 
cm in thicker tumors80. Radiotherapy is another treatment of choice that is inferior 
to surgery. Radiotherapy is an alternative treatment option for inoperable tumors81. 
In macroscopic tumors the radiation recommended dose is 70 Gy, five sessions per 
week with two individual doses of 2 Gy individually. In microscopic tumors, the 
radiation recommended does is 60 Gy with individual doses of 2 Gy.  Three 
dimensional radiation planning should be performed to guarantee the radiation 
homogenous distribution in the affected sites and to spare the adjacent normal 
tissues82. In case of inoperable recurring tumors, inoperable local metastases, and 
stage IV metastases melanoma the recommended treatments are chemotherapy and 
chemo-immunotherapy83.  
 
As for advanced stages of melanoma, systemic mono-therapy with several 
substances that have high clinical effectiveness is available. The mechanism here is 
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that mono-chemo therapy has the ability to shrink tumor cells and decrease tumor 
symptoms. The mono-therapy medical drugs used and recommended worldwide 
are listed in the table below84.  
 
Drug  Dosage  Responsiveness rate 
Dacarbazine 250 mg/m2 i.v., days 1–5 every 3–4 weeks  
Or 800–1200 mg/m2 i.v., day 1 every 3-4 weeks 
12.1–17.6% 
5.3–23% 
Temolozomide 150–200 mg/m2 oral, days 1–5 every 4 weeks 13.5–21% 
Fotemustine 100 mg/m2 i.v. days 1, 8, and 15, followed by 5 week 
interval, to be repeated every 3 weeks 
7.4–24.2% 
Vindesine 3 mg/m2 i.v. every 14 days 12–26% 
Interferon alpha 9m–18m IU/m2 s.c. 3×/week continuous administration 13–25% 
Interleukin-2 600 000 IU/kg as 15 minute short infusion i.v. every 8 
hours on days 1–5 (maximum 14 individual doses), 
repeat cycle day 14 
16–21.6% 
Table 1: The mono therapy medical drugs and recommended worldwide. 
 
 
Due to the high ability of melanoma to become metastatic, and the limited 
therapeutic choices for inoperable tumor, medicine lately follows the adjuvant 
therapeutic approaches. The most adjuvant therapy used for ulcerating primary 
tumors is interferon, thus decreasing patient’s mortality. Depending on the patient 
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status low dose or high dose treatment with interferon alpha is applied85.High and 
low interferon alpha-2 recommended doses are listed in Table 2.  
Scheme Dosage 
Low dose interferon alpha-2 3m IU s.c. 3×/week  over 18–24 months 
High-dose interferon alpha-2b 
Initial treatment 
20m IU/m2 i.v., days 1–5 over 4 weeks 
 
Maintenance treatment 10m IU/m2 s.c., 3×/week over 11months 
Table 2 : High and low interferon alpha-2 recommended doses. 
 
 
4. Melanoma Mutations  
 
4.1. NRAS mutation  
Ras proteins play an important role in molecular switching for transmission of the 
regulatory signals since they are involve with the intrinsic GTPase activity and 
cycle between inactive GDP-bound form and active GTP- bound form86. Huge 
numbers of reports indicate that RAS gene mutation screening in melanoma tumors 
have been observed since they appeared in literature, and there are three closely 
related proto-oncogenes, encoding the H-Ras, K-Ras and N-Ras proteins, 
respectively are habitually found in their mutated oncogenic forms in human 
tumors87.  
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Around 20% of human tumors have activating RAS point mutations. These 
mutations mainly found in codons 12, 13 or 61, and these investigations 
consistently point to NRAS codon 61 as being the most common RAS alteration in 
primary sporadic melanomas, with reported frequencies fluctuating from 4 to 50%. 
Where the most frequently observed NRAS codon 61 mutations are the Q61R 
(CAA/CGA) and Q61K (CAA/AAA) changes leading to substitutions from 
glutamine to arginine or to lysine respectively88. Activating mutations in the KRAS 
and HRAS genes were in contrast, recorded at very low incidences89. RAS gene 
affected by tumor specific mutations, since for example carcinomas of the 
pancreas; the colon and lung all have high occurrences of KRAS mutations90. 
While NRAS mutations, are common in myeloid leukemias and among CM91. 
 
In the active form of GTP-bound, RAS stimulated three closely associated 
proteins, A-RAF, B-RAF, and C-RAF. Hence activated RAF will bind to the 
plasma membrane, phosphorylates and activates MAP-kinases Mek1 and Mek2, 
consequently the mitogen activated kinases Erk1 and Erk2 are phosphorylated and 
activated which leads at the end to ETS protein family phosphorylation. In addition 
to that, there are extra cytoplasmic proteins, capable to permit the nuclear 
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membrane, and activate the nuclear transcription factors Fos and Jun. The final 
consequence is the expression of cyclin D and other regulators in the cell cycle, 
leading to progression and transformation in it, with an additional functions which 
are regulated by the MAPK pathway, such as cells differentiation, senescence and 
apoptosis or survival92.  
 
Another effecter pathway which RAS acts; is its ability to interact with type I 
phosphatidylinositol-3-kinases (PI3Ks) leading to anti apoptotic effects. In addition 
to that it can regulate the actin cytoskeleton and other transcription factor pathways 
by helping of Rac and Rho family of proteins. Also it can affect the RAL proteins 
by RAL guanine nucleotide dissociation stimulators (RALGDS) and other 
associated proteins with additional effects for cell cycle regulation. Another RAS 
related activity done by phospholipase C linking RAS to Protein Kinase C (PKC) 
activation and calcium mobilization93.  
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Figure 5: NRAS pathway  
 
 
 
4.2.  BRAF mutation 
BRAF is a serine/threonine kinase encoded on chromosome 7q3494. It activates the 
MAPK, Erk, Erk cascade, interacting directly with MAPK and Erk 1. In addition, 
it plays a role as ant apoptotic, although the mechanism for this function is not 
clear95.  The most common BRAF mutation detected in overall tumors including 
melanoma is codon 600 valine to glutamate (V600E) mutation96. Around 80% of 
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benign nevi carry this mutation97. BRAF V600 is sited in the activation segment of 
the kinase domain adjacent to T599 and S602, which are on phosphorylation 
outcome in kinase activity98. The V600E mutation may mimic the T599/S602 
phosphorylation since V600E mutant BRAF has an advanced kinase activity than 
wild type BRAF99.  
 
BRAF mutation incidences range from 20–80%. Among the BRAF mutations 
observed in melanoma, over 90 % are at codon 600, and amongst these, over   90% 
are a single nucleotide mutation as a result in substitution of glutamic acid for 
valine (BRAF V600E: nucleotide 1799 T>A; codon GTG> GAG). The second 
most common mutation is BRAF V600K, a result of lysine for valine substitution 
that represents 5-6 % (GTG> AAG). Followed by BRAF V600R mutation, as a 
result of substitution of valine (V) to an arginine (R)(GTG> AGG), an infrequent 
two-nucleotide variation of the predominant mutation, BRAF V600 ′E2′ (GTG> 
GAA), and BRAF V600D (GTG> GAT) mutation from valine (V) to an aspartic 
acid (D)100.  
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4.3.  C.KIT mutation  
At the molecular level, BRAF and NRAS mutations have been rarely found in 
MM101, whereas the gene encoding receptor tyrosine kinase KIT mutations and or 
increased in copy numbers have been seen in up to 40% of MM102. The thing that 
makes KIT is the most commonly altered oncogene recognized in MM so far. This 
opened the door for MM treatment option concerning the target therapy for this 
gene, which becomes more obvious after noticing the clinical response of KIT-
mutated MM to tyrosine kinase inhibitors such as Imatinib, sorafenib and 
dasatinib103. 
 
 
 
Several processes including proliferation, survival and apoptosis will be affect 
when mutation in c-kit gene occurs since it works as a tyrosine kinase receptor, 
which stimulates multiple downstream signaling cascades, such as MEK, RAF, 
ERK and PI3K, AKT pathways104. Hence, the transformed melanocytes express 
abnormalities in the c-kit, in the endothelin receptor type B, endothelin pathway, 
and in the Wnt/β -catenin pathway, in addition to that, it shows abnormality in cell-
adhesion molecules105. In atypical melanocytes, increase c-kit protein expression is 
mainly associated with activating mutations suggesting a relevant function of the 
proto-oncogene KIT in the progress of oral mucosal melanoma106. 
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5. Materials and methods  
 
 
5.1.  Tumor samples 
 
Twenty-four melanoma cell lines were obtained from Dr. Lotem’s Laboratory in 
Hadassah medical center. These cell lines were established from Palestinian 
melanoma patients. Ten cell lines represented cutaneous melanoma isolated from 
various body sites including ear, leg, scalp and facial areas. Twelve cell lines have 
been isolated from mucosal lesions from various body sites including vaginal, 
ocular, uveal and nasal. In addition, three cell lines were taken and developed from 
acral melanoma patients.  
 
 
 
 
5.2. Cell culture  
 
The melanoma cell lines were grown and maintained in the tissue culture lab 
following strict aseptic conditions inside a biosafety cabinet with laminar air flow. 
In brief, the frozen cell lines were rapidly thawed at 37o C and seeded in DMEM 
medium containing 10% FBS, antibiotics and anti-fungal agents. The cells were 
transferred to a 25 mm tissue culture flask containing 7 ml of the DMEM medium, 
incubated in 5% CO2 for 24 hours. The flasks were then viewed under the inverted 
microscope to check if cells attached and to ensure the absence of contamination. 
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The old medium was then discarded and replaced with fresh DMEM medium. 
Thereafter, the cells were monitored and medium was change dafter 3 days until 
the cells achieved 80-90% confluency. The cells were then collected by adding 1 
ml of 0.25% trypsin, incubated for 3-5 minutes, and the detached cells were 
collected in 15 ml sterile conical centrifuge tube. After centrifugation for 7 minutes 
at low speed (800 x g or 1000 rpm), the supernatant was removed and replaced by 
5-10 ml fresh DMEM medium depending on the cell count. 
 
 
 
 
 
Figure 6: Melanoma cell culture using inverted microscope magnification 10X. 
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Figure 7: Melanoma cell culture using inverted microscope magnification 10X. 
 
 
 
 
 
Figure 8: Monolayer of aggressive mucosal melanoma growth after 48 hours. 
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Figure 9: Monolayer of aggressive mucosal melanoma growth after 48 hours. 
 
 
 
 
 
 
5.3.  DNA extraction  
 
DNA was extracted from the twenty-five cell lines collected by the salting out 
method according to a standard protocol. One ml of cell suspension was placed in 
1.5 ml microcentrifuge tube, centrifuged to sediment the cells and the supernatant 
removed. This was followed by adding 600 µl of TNES buffer to the 
microcentrifuge tube containing the cells (prepared by mixing 10 mM Tris, pH 7.5 
and 100 mM EDTA to regulate the lysate osmolarity and acidity, and 400 mM 
NaCl, 0.6 % SDS detergent to break up membrane structure and 40 µl of 
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Proteinase-K). Then incubated in a water bath at 55o C for 30 minutes with the 
microcentrifuge tubes lids are tightly closed and tubes inverted several times to 
mix the samples. After that,7 µl of 6 M NaCl were added to the samples and mixed 
for 20 seconds taking into consideration not to damage the DNA. Then the samples 
were centrifuged for 5-10 minutes at 12-14000 RPM at room temperature, and the 
supernatant removed and placed into new 1.5 ml microcentrifuge tubes.  Absolute 
ice-cold ethanol (800 µl) was added to the samples and mixed gently by inverting 
the tubes several times; the DNA precipitate can be seen as a white sting. The 
samples were then centrifuged at 12-14,000 RPM for 10-20 minutes at 4ºC. The 
pellet containing the DNA was washed by adding200-700 µl of 100% ethanol by 
gently inverting the tubes, the ethanol was poured off and samples briefly spun to 
keep the pellet at the bottom of the tubes.  
After repeating the washing step with 70% ethanol as above and removing excess 
ethanol by centrifugation, (ethanol inhibits the PCR amplification), the samples 
were left for 10-30 minutes to air dry. The DNA in the samples were finally 
suspended in 100-200 µl sterile distilled water or Tris-EDTA.  
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The purified DNA has been examined qualitatively by agarose gel electrophoresis 
to ensure the presence of intact high quality product. Quantitatively, the yield was 
determined by nano-drop instrument (Thermo nano-drop) using 260 nm, 280 nm 
wavelengths.  The ratio was determined to ensure the purity of the products.  
Then the DNA samples went through normalization process to make all of them 
get the same concentration30 ng/ul by distilled water. After that, we used C1000- 
thermo cycler “Bio-Rad” PCR apparatus, and the samples used the following 
program: 
 
  Initial denaturation at 94 °C for 5 min followed by 35 cycles of 
  Denaturation at 94 °C for 30 seconds 
 Annealing at 56 °C for 1 min 
 Extension at 72 °C for 1 min. 
  Final extension step at 72 °C for 7 min.  
 
Then the PCR products were separated in 2% agarose gel electrophoresis to ensure 
the quality of the products. The bands were excised, and purified using the QIA 
quick Gel Extraction Kit (Qiagen). Thereafter, sequencing was carried out using 
the Big Dye Terminator v1.1 Cycle Sequencing Kit (Applied Bio systems) on a 
3130xl Genetic Analyzer (Applied Bio systems). 
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5.4.  Mutational analysis  
 
Screening for possible mutations in the BRAF gene exon 15, NRAS Q61 exon 3, 
and C-KIT exon 11, 13, and 17 were carried out by PCR and Sanger sequencing. 
The primers used for amplification and subsequent gene mutations are shown in 
Table 3. 
 
 
Oncogene Primer Amplicon 
(bp) 
Reference  
BRAF (V600E) 
(exon15) 
F-5’TCATAATGCTTGCTCTGATAGGA3’ 
R-5’ GGCCAAAAATTTAATCAGTGGA 3’  
224 bp 107 
NRAS (Q61) F-5’ GAACCAAATGGAAGGTCACA3’ 
R-5’ TGGGTAAAGATGATCCGACA3’ 
301 bp 107 
C-KIT (exon11) F-5’ GATCTATTTTTCCCTTTCTC 3’ 
R-5’ TTATGTGTACCCAAAAAGG 3’ 
203 bp 104 
C-KIT (exon13) F-5’ -GCGTAAGTTCCTGTATGGTA 3’ 
R-5’ AACCTGACAGACAATAAAAG 3’ 
237 bp 104 
C-KIT (exon17) F-5’ AAAGATTTGTGATTTTGGTCTAGC 3’ 
R-5’ GAAACTAAAAATCCTTTGCA.3’ 
116 bp 104 
Table 3: The primers used for each gene mutations 
 
 
The amplification was carried out in a total volume of 25 ul, consisting of the 
following: 12.5 ul of 1X ready master mix (containing 0.625 U thermos prime Taq 
DNA polymerase, 75 mM Tris-HCL (pH 8.8), 20 mM (NH4)2SO4, 0.2 mM 
dNTPs, 1.5 mMMgCl2), 0.28 mM each of forward and reverse primers, 9.3ul 
distilled water and 2 ul (50ng/ul) Genomic DNA.  
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6. Results 
 
The aim of this work was to determine the types of mutations in cutaneous, 
mucosal and acral melanoma cell lines isolated from various anatomical sites from 
Palestinian patients. PCR was performed to obtain products from 5 exons and 
subsequently sequenced to determine the presence or absence of mutations. 
The amounts of DNA extracted from the cell lines ranged from 12.1 to 269.7 ng/ul 
with an average of 86.3 ng/ul.  The ratio of 260/280 was ≤ 1.8 indicating a high 
quality DNA product. 
The total numbers of mutations were found in seven cell lines predominantly in 
cutaneous melanoma. Mutations were detected in 29% (7/24) of the cell lines 
tested. Most mutations were found in BRAF V600E oncogene in cutaneous 
mutations of the skin accounting for 57.1% (4/7). Cutaneous mutations of the 
NRAS Q61R type isolated from ocular tumor was found in 14.2% (1/7) of the 
cells. Mucosal mutation of the c-KIT oncogene was detected in two cell lines with 
a rate of 29% (2/7). KIT 11 V559A type was found only in one cell line with a rate 
14.2% (1/7). The other mutation was found in KIT13 M651R type in only one cell 
line with a rate of 14.2% (1/7). The remaining cell lines tested were negative for all  
tested mutations. The results are summarized in Table 4. 
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Sample ID DNA Conc. Primary Site  BRAF NRAS KIT 11 KIT 13 KIT 17 
CL001 80.7 ng/ul Scalp V600E WT WT WT WT 
CL002 132.9 ng/ul Leg WT WT WT WT WT 
CL003 161.2 ng/ul Mucosal WT WT WT WT WT 
CL004 93.1 ng/ul Scalp V600E WT WT WT WT 
CL005 194.8 ng/ul Skin of Ear WT WT WT WT WT 
CL006 195.1 ng/ul Ocular WT Q61R WT WT WT 
CL007 73.4 ng/ul Leg WT WT WT WT WT 
CL008 87.8 ng/ul Acral WT WT WT WT WT 
CL009 269.7 ng/ul Vagina WT WT WT WT WT 
CL010 192.3 ng/ul Acral WT WT WT WT WT 
CL011 128.9 ng/ul Scalp WT WT WT WT WT 
CL012 33.5 ng/ul Acral WT WT WT WT WT 
CL013 104.5 ng/ul Scalp V600E WT WT WT WT 
CL015 52.3 ng/ul Mucosal WT WT WT WT WT 
CL014 79.6 ng/ul Facial V600E WT WT WT WT 
CL016 24.5 ng/ul Uveal WT WT WT WT WT 
CL017 42.2 ng/ul Uveal WT WT WT WT WT 
CL018 16.7 ng/ul Mucosal WT WT WT WT WT 
CL019 17.4 ng/ul Mucosal WT WT WT M651R WT 
CL020 16.7 ng/ul Mucosal WT WT WT WT WT 
CL021 17.3 ng/ul Mucosal WT WT WT WT WT 
CL022 24 ng/ul Mucosal WT WT V559A WT WT 
CL023 12.1 ng/ul Uveal WT WT WT WT WT 
CL024 20 ng/ul Uveal WT WT WT WT WT 
Table 4: represents the cell lines tested, DNA concentration and the type of mutations.  
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Controls for the mutations detected are shown in Figure 10. The sizes of the 
oncogenes (BRAF, NRAS ,CKIT11, CKIT13, and CKIT17) responsible for the 
mutations were; 350, 256, 390, 400, 470 and  base pairs respectively. 
 
Figure 10: Agarose gel electrophoresis of PCR for controls: Lane”1”: BRAF (350 bp), Lane “2”: NRAS 
(256 bp), Lane”3”: CKIT 11 (390 bp), Lane “4”: CKIT13 (400bp),  , Lane”5”: CKIT 17 (470 bp) controls 
 
This Figure illustrates the CKIT products for two collections 1 and 2, CKIT 11 and 
CKIT 13 with sizes ranging from 380-390 bp and 375-400 bp respectively. 
Samples number 2 and 3 in collection 1 and samples number 2, 3, 4, 6, 8, and 10 in 
collection 2 are not appear that well so they are repeated in the next figure. In 
addition to samples number 4, 6, 8 and 10 in collection 1 since unlike other 
samples they are slightly fading.  
Figure 11: Agarose gel electrophoresis of PCR for Collection“1”:CKIT 11, 380-390 bp and Collection 
“2”: CKIT 13, 392-400 bp. 
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The three collections 1, 2 and 3 show the DNA bands for the unclear ones repeated 
for CKIT 11, CKIT 13 and unrepeated ones for CKIT 17 with sizes ranging from 
392- 397 bp, 395-400 bp, and 465-470 bp respectively.     
 
Figure 12: Agarose gel electrophoresis of PCR products for Collection”1”:CKIT 11, 392-397 bp, 
Collection“2” CKIT 13: 395-400 bp, repeated bands and Collection“3” CKIT17: 465-470 bp.  
 
 
The figure below shows the DNA products for BRAF gene that range in size 
between 320-350 bp. Band number’s 4 appears fading and not clear, so it is 
repeated again in the next figure.  
 
Figure 13: Agarose gel electrophoresis of PCR for BRAF with sizes ranging between 320-350 bp.  
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The figure below shows the DNA products for BRAF gene samples starting with 
the repeated one number 4 ranging in size between 320-340 bp.  
 
Figure 14: Agarose gel electrophoresis of PCR for BRAF ranging in size between 320-340 bp.  
 
 
This figure illustrates the NRAS gene products with sizes ranging between 250-
256 bp.  
 
Figure 15: Agarose gel electrophoresis of PCR for NRAS 250-256 bp.  
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This figure shows the WT reverse image for the BRAF Sanger sequencing. The 
mutation we are looking for should be found in the highlighted area when the 
sample has mutation.  
 
Figure 16: Sanger sequencing of BRAF WT reverse (Bethlehem University, Palestine).    
 
 
The figure below shows the forward mutation for the BRAF gene in the 
highlighted area. The mutation found is point mutation BRAF V600E, where 
glutamic acid is substituted to valine.  
Figure 17: Sanger sequencing of BRAF mutation forward (Bethlehem University, Palestine).    
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The figure below illustrates the forward WT Sanger sequencing for NRAS gene. 
Where the suspected mutation should be found in the highlighted area.  
Figure 18: Sanger sequencing of NRAS WT forward (Bethlehem University, Palestine).    
 
 
This figure shows the reverse WT Sanger sequencing for NRAS gene.   
Figure 19: Sanger sequencing of NRAS WT reverse (Bethlehem University, Palestine).    
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This figure illustrates the highlighted mutational area in NRAS gene forward. The 
point mutation that found is Q61R where glutamine is substituted to arginine.  
Figure 20: Sanger sequencing of NRAS forward mutation (Bethlehem University, Palestine 
 
 
The figure below shows the Sanger sequencing of WT KIT exon 11 L576P. In case 
of mutational presence there will be a substituion of Leucine to Proline, so we will 
see C instead of T. This mutation is considered the most common KIT mutation in 
melanoma with a ratio accounts in range 30-40%108.  
 Figure 21: Sanger sequencing of CKIT 11 WT forward (Bethlehem University, Palestine).    
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The figure below shows the WT Sanger sequencing for KIT exon 11 V559A.   
 Figure 22: Sanger sequencing of CKIT 11 WT forward (Bethlehem University, Palestine).    
 
The figure below illustrates the mutational form for the previous WT mutation, 
where the mutation found is V559A, a substitution of Valine to Alanine at position 
559. This mutation accounts around 20% of MM.  
 Figure 23: Sanger sequencing of CKIT 11 mutation (Bethlehem University, Palestine).    
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This figure illustrates the WT exon 13 of K642E substitution of Lysine to Glutamic 
acid. If there is a mutation the highlighted A will convert to G. this mutation 
accounts up to 20% of MM109.  
 Figure 24: Sanger sequencing of CKIT 13 WT (Bethlehem University, Palestine).    
 
 
The figure below shows the forward WT Sanger sequencing of CKIT 13. 
Figure 25: Sanger sequencing of KIT 13 WT (Bethlehem University, Palestine).    
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This figure shows M651R  mutation that found in Sanger sequancing of CKIT 13. 
This mutation is result from substitution of Methionine to Arginine, and it not 
found in litreture therefore it is maybe considered as norval mutation.  
Figure 26: Sanger sequencing of CKIT 13 mutation (Bethlehem University, Palestine).    
 
 
The figure below illustrates the WT Sanger sequencing of D816H exon 17. In case 
of mutational presence, there will be an amino acid substitution from an Aspartic 
acid to Histidine.  
Figure 27: Sanger sequencing of CKIT 17 WT (Bethlehem University, Palestine).    
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7. Discussion 
 
This work has been conducted on 24 cell lines established from Palestinian patients 
with melanoma, which included cutaneous and mucosal types. The aim of the 
study was to determine the type and rate of mutations in these cell lines. 
 
The identification of gene mutations in all types of melanoma (CM, MM) from 
various body sites has provided significant information regarding the progression 
of molecular target therapies for this disease. These mutations have been identified 
to occur in multiple oncogenes primarily BRAF, GNAQ, KIT, MEK1 (MAP2K1) 
and NRAS. Mutations in these oncogenes were the most common and found in 
about 70% of all melanoma mutations. However, Somatic mutations in GNA11 
and GNAQ have been primarily identified in uveal melanoma and its metastasis110. 
Furthermore, somatic mutations in MEK1(MAP2K1) have been found in 6% of 
malignant melanomas111, but their prevalence in melanoma subtypes has not yet 
been determined. The therapeutic role that MEK1 mutations is extremely low112. 
Therefore, these genes were not included in the panel of oncogenes (BRAF, NRAS 
and KIT subtypes) investigated in this project. 
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Our data in this study showed that the most common oncogene mutation 
incriminated in cutaneous melanoma was BRAF V600E, where glutamic acid is 
substituted to valine, which accounted for 66.7% (4/6). This finding is close to the 
rate reported for somatic mutations in BRAF of 20-80% as mentioned above. The 
second and third most common mutations reported after BRAF V600E were 
BRAFV600K and BRAFV600R respectively. These mutations have not been 
detected in the sample tested in this study. The head and neck melanoma are the 
most common sites where cutaneous melanoma occurs in men113.  
 
BRAF mutations are mainly involved in the induction of genomic instability, and 
enhancing with a high frequency the melanocytes proliferation, e.g. the mutated 
BRAF signals as an autonomous monomer of upstream growth stimuli, especially 
in BRAF V600E, which causes kinase activation as well as negative feedback 
mechanics insensitivity. This mutation is also involved in other mechanisms 
related to melanoma progression, mainly the downstream MEK/ERK pathway 
activation, apoptosis and senescence elusion. In addition to that, it plays an 
important role in tissue invasion and metastasis by up regulation of many proteins 
that are implicated in cell contractility, migration, integrin signaling, tumor and 
microenvironment- derived interleukin-8, as well as angiogenesis by MEK- 
dependent activation of HIK-11α and VEGF114.  
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Another oncogene that has been investigated in this study was NRAS. Somatic 
mutations in this oncogene have been reported in about 13-25% of all malignant 
melanomas115. In this study, the rate of somatic mutations in NRAS oncogene in 
the tested cell lines was 14.2% (1/7), similar to that reported in literature. It has 
been known that mutations in NRAS Q61 oncogene occurring in exon 3 are 
missense mutations resulting in the substitution of amino acids at positions 12, 13 
or   Q61.  Glutamine residue is usually substituted by lysine or arginine.  Although 
somatic mutations in both BRAF and NRAS oncogenes are associated strongly 
with UV light, the NRAS mutations do not overlap with other mutations caused by 
other oncogenes such as BRAF and KIT. 
 
BRAF and NRAS sharing the same pathway, consequently one of them or both 
could be activated according to the pathway track. Since the MAP kinase signaling 
pathway activates set up an obligatory step in the transformation of melanocytes, 
and small interfering RNA “siRNA” depleting B-raf in BRAF V600E melanocytes  
as well as siRNA mediating silencing of N-ras in NRAS codon 61 mutant 
melanocytes inhibits Erk activation and results in apoptosis. Based on that NRAS 
considered the second most common oncogenic driver mutation in melanoma. 
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Hence, the intracellular pathway has been activate and induces cell cycle 
dysregulation, pro-survival pathways, and cellular proliferation116. 
 
Somatic mutations in KIT oncogene have been reported in all melanoma subtypes. 
However, these mutations are most common in acral melanomas at rate of 10-20% 
and the gene encoding receptor tyrosine kinase KIT mutations and or increased in 
copy numbers have been seen in up to 40% of MM 117,118 .The KIT oncogene 
encodes a protein that functions in controlling cell division. It causes abnormalities 
in several areas such as nail beds, palms, soles or mucous membranes. Somatic 
mutations on KIT gene are not associated with UV light. The most common 
mutations, which could be found in MM, are L576P that accounts the highest 
mutational ratio, followed by K642E, V559A, and D816H. These mutations 
account around 50% of all KIT mutations in literature.   
 
The rate of KIT mutations observed in this study was 29% (2/7) which is similar to 
that reported in literature as mentioned previously. As reported, this oncogene 
causes melanomas in several body sites including mucous membranes. The first 
mutation has been detected in CL022 that has been established from mucosal 
melanoma site. This mutation appeared in KIT 11 by substitution of Valine to 
Alanine at position 559. This mutation accounts around 20% of all MM.119 The 
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second mutation has been detected in the cell line number CL019 which was 
established from a mucosal melanoma case too.  This mutation appeared in KIT13 
by substitution of methionine to arginine at position 651. Somatic mutations for 
KIT17 were not detected in the cell lines tested. The frequency of KIT mutations in 
primary MM varies notably with its anatomical site, respiratory, gastrointestinal 
and urogenital tracts. The Kit mutations are typically amino acid substitutions in 
11, 13 or 17 exons, while the KIT mutation which is found in gastrointestinal 
melanocytes occur as a results of deletion or insertion in exon 11120.  The KIT 
mutations in melanocytes consequently affect the juxtamembrane domain of the 
KIT protein leading to constitutive activation of KIT ligand binding of the tyrosine 
kinase of C-KIT independently121.  
This mutation is not found in literature therefore it is maybe considered as novel 
mutation. 
 
In general, mucosal and acral melanomas are considered the most common 
subtypes in Asian population 122 . This comprises greater than 70% of all 
melanomas, a rate that is much higher than that seen in white 
populations123.  Therefore, c-Kit mutations are likely the most common kind of 
genetic mutations in Asians, and the investigation of c-Kit inhibitors is a high 
priority in this population124.  
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Only few researches have been published related to this field in Arab’s world. In 
Jordan, there are no previous comprehensive Jordanian studies on melanoma and 
proper statistical data on morbidity and incidence are nonexistent125. However, 
they studied the histopathology records of CM samples in 2008 and analyzed them 
in accordance to their clinical data, to evaluate their experience in CM at King 
Hussein Medical Center126. Nevertheless, there are no studies about MM. While in 
Lebanon, they recently studied the rate of different BRAF mutation types, and 
assessed correlations with prognostic markers and potential UVR exposure127. In 
addition, there are some studies in diagnosis of melanoma to assess the frequency 
of occurrence and risk factors for MM128. There is no specific study about MM, but 
there are some studies about treatment of MM, Imatinib in patients with mucosal 
or acral lentiginous melanoma, to evaluate how effective Imatinib in treating these 
types of melanoma in patients whose disease carries a c-kit mutation129.  
 
In Egypt, the incidence rate of melanoma is very low and its topographic 
distribution is different130. For this reason, melanoma studies are rare there, so they 
studied the extra cutaneous malignant melanomas, reporting several cases131. In 
addition, they studied the molecular mechanisms for melanoma and other skin 
cancers caused by UV radiation132. immunohistochemical expression in CM such 
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as Ephrin A4133, also its association with hepatitis C virus134. No articles have been 
published about MM; only in 2014, they published case report about gastric 
metastases from invasive MM135. As for Saudi Arabia, they published an article in 
2012 studied CM from 1995-2011 at King AbdulAziz university hospital, found 
that CM accounts 11.5% of population while 68.7% are ALM136. In Iraq, they 
published last year an article about melanomas there, and they found that the most 
common and aggressive one is the ALM 75%, with a lesser amount of CM137, no 
direct studies about MM there. However, in Iran they studied MM, to investigate 
incidence, sex, age and site distribution of MM of the head and neck138.  
 
In Tel Aviv university Sourasky medical center/Israel, they published an article 
about two p16 (CDKN2A) germ line mutations in 30 Israeli melanoma families139. 
Another two cases report in rectal malignant melanoma have been published in 
Carmel medical center, Haifa140. While in Hadassah university hospital, Jerusalem 
they studied MM in nine cases of the female genital tract141.  
In Palestine no studies have been done in MM neither CM. for this reason we want 
to make a study on this subject, and compare between CM and MM/ ALM 
mutations at the molecular level.  
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